Change of Adviser

Embargoed: 0700hrs 8 September 2014

Akers Biosciences, Inc.

(the "Company")

Appointment of nominated adviser and broker

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce the appointment of finnCap as nominated adviser and broker with immediate effect.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found on our website at www.akersbiosciences.com. Follow us on Twitter @AkersBio.

For more information:

Raymond F. Akers, Jr. PhD

Executive Chairman

Akers Biosciences, Inc.

Tel. +1 856 848 8698

Twitter. @AkersBio

finnCap (UK Nominated Adviser and Broker)

Geoff Nash / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

Tel: +44 (0)20 7220 0500

Ben Simons / Alexandra Roper

Vigo Communications (UK Investor Relations)

Tel. +44 (0)20 7016 9570

Email: [email protected] 

Brendan Hopkins

RedChip Companies, Inc. (US Investor Relations)

Tel. +1 407 644 4256 x134